Enteropathogenic Infection Induces Diarrhea, Intestinal Damage, Metabolic Alterations, and Increased Intestinal Permeability in a Murine Model
Overview
Infectious Diseases
Microbiology
Authors
Affiliations
Enteropathogenic (EPEC) are recognized as one of the leading bacterial causes of infantile diarrhea worldwide. Weaned C57BL/6 mice pretreated with antibiotics were challenged orally with wild-type EPEC or mutant (lacking type 3 secretion system) to determine colonization, inflammatory responses and clinical outcomes during infection. Antibiotic disruption of intestinal microbiota enabled efficient colonization by wild-type EPEC resulting in growth impairment and diarrhea. Increase in inflammatory biomarkers, chemokines, cellular recruitment and pro-inflammatory cytokines were observed in intestinal tissues. Metabolomic changes were also observed in EPEC infected mice with changes in tricarboxylic acid (TCA) cycle intermediates, increased creatine excretion and shifts in gut microbial metabolite levels. In addition, by 7 days after infection, although weights were recovering, EPEC-infected mice had increased intestinal permeability and decreased colonic claudin-1 levels. The mutant colonized the mice with no weight loss or increased inflammatory biomarkers, showing the importance of the T3SS in EPEC virulence in this model. In conclusion, a murine infection model treated with antibiotics has been developed to mimic clinical outcomes seen in children with EPEC infection and to examine potential roles of selected virulence traits. This model can help in further understanding mechanisms involved in the pathogenesis of EPEC infections and potential outcomes and thus assist in the development of potential preventive or therapeutic interventions.
Etiology and risk factors of hemorrhagic abomasitis in goat kids.
Esmaeili H, Almasi Chegeni S, Joghataei S, Lotfalizadeh Mehrabadi P, Shokrpoor S Sci Rep. 2025; 15(1):6133.
PMID: 39972071 PMC: 11840130. DOI: 10.1038/s41598-025-90904-5.
Arredondo-Hernandez R, Siebe C, Castillo-Rojas G, Ponce de Leon S, Lopez-Vidal Y Front Antibiot. 2025; 1():1001717.
PMID: 39816412 PMC: 11732057. DOI: 10.3389/frabi.2022.1001717.
Dong C, Chen Y, Ding M, Liu Y, Chen X, He Y Int J Mol Sci. 2024; 25(19).
PMID: 39409065 PMC: 11477028. DOI: 10.3390/ijms251910736.
Antibacterial peptide Reg4 ameliorates -induced pulmonary inflammation and fibrosis.
Wan X, Wang W, Zhu J, Xiao Y Microbiol Spectr. 2024; 12(5):e0390523.
PMID: 38501823 PMC: 11064540. DOI: 10.1128/spectrum.03905-23.
Theodorou V, Beaufrand C, Eutamene H Drugs Context. 2023; 12.
PMID: 37908642 PMC: 10615328. DOI: 10.7573/dic.2023-5-2.